Monte Rosa Therapeutics
monterosatx.com · Technology · GLUE
Ranked 1,439 of 2,047 companies in the study
- Visibility4
- Citations0
- Sentiment50
- Site quality80
- AI readiness29
AI assistants rarely name Monte Rosa Therapeutics, mentioning it in 1 of 60 answers, sometimes along with Arvinas. Its overall score is 28 out of 100, ranking 1,439th of 2,047 in the study and 220th of 273 in the Technology sector. The company's website passes 4 of 14 technical checks for AI tool readiness.
We asked 15 unbranded questions about the technology market: none named Monte Rosa Therapeutics. AI assistants named it in 1 of 60 answers (1.7%). The typical technology company is named in 10.0% of answers. By how often it is named, Monte Rosa Therapeutics ranks 211 of 273 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
273 companies in this sector. The line on each bar is the typical company.
An answer that names the company
“What are the current clinical trial trends in molecular glue degraders for cancer?”
Molecular glue degraders (MGDs) are a rapidly evolving area in cancer treatment, offering a novel approach to target previously "undruggable" proteins by hijacking the cell's natural protein degradation machinery. This involves promoting interactions between an E3 ubiquitin ligase and a target protein, leading to the target's ubiquitination and subsequent destruction.
Here are some current clinical trial trends in molecular glue degraders for cancer:
1. Expanding "Undruggable" Targets:
A significant advantage of MGDs is their ability to target proteins that traditional small molecule …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 1: Basic web presence. Two of robots.txt, a sitemap and Link headers are in place.
- Content Signals
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapPassed
An XML sitemap listing the pages, ideally referenced from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 25 of 100 · 97% of checks could run · checked on October 5, 2026 · www.monterosatx.com · 2,047 companies scanned
4 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- PassedHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets no rules for any AI crawler by name, like 84% of the websites whose rules we could read. Every AI crawler follows its general rules.
- GPTBotallowed
- ClaudeBotallowed
- Anthropic-AIallowed
- Google-Extendedallowed
- Applebot-Extendedallowed
- Meta-ExternalAgentallowed
- FacebookBotallowed
- Bytespiderallowed
- CCBotallowed
- Diffbotallowed
- Omgilibotallowed
- OAI-SearchBotallowed
- Claude-SearchBotallowed
- PerplexityBotallowed
- Applebotallowed
- Amazonbotallowed
- YouBotallowed
- ChatGPT-Userallowed
- Claude-Userallowed
- Perplexity-Userallowed
- DuckAssistBotallowed
- MistralAI-Userallowed
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as US-listed.
- Are next-generation targeted protein degraders worth considering for drug development pipelines?
- What role do AI and proteomics play in the discovery of protein degradation therapies?
- What alternatives are available for targeting disease-causing proteins beyond degradation approaches?
- What are the leading advancements in protein degradation therapies for cancer treatment?
- How are pricing models for protein degradation drugs established in the oncology market?
- Which types of diseases could benefit most from targeted protein degraders?
- Is investing in protein degradation platforms promising for oncology breakthroughs?
- What are the current clinical trial trends in molecular glue degraders for cancer?
- Protein degradation vs. traditional small molecule inhibitors—what are the advantages and limitations?
- How do molecular glue degraders differ from PROTACs in therapeutic applications?
- Which other pharmacological strategies compete with protein degradation for modulating intracellular targets?
- What challenges are common when advancing protein degradation candidates to clinical trials?
- How can protein degradation be applied to target undruggable cancer proteins?
- Why might a protein degradation therapy fail to achieve target specificity?
- What factors influence the cost of developing new targeted protein degradation medicines?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.